Notice of Award
First Responders  
Department of Health and Human Services  
Substance Abuse and Mental Health Services Administration  
Center for Substance Abuse Prevention

Issue Date: 10/10/2019

Grant Number: 6H79SP080319-03M001  
FAIN: H79SP080319  
Program Director: Karen Wallace

Project Title: Missouri Overdose Rescue and Education (MORE) project

Organization Name: MISSOURI STATE DEPT/ HEALTH & SENIOR SRV

Business Official: Tonya Loucks

Business Official e-mail address: grants@health.mo.gov

Budget Period: 09/30/2019 – 09/29/2020  
Project Period: 09/30/2017 – 09/29/2021

Dear Grantee:

The Substance Abuse and Mental Health Services Administration hereby awards a grant in the amount of $0 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to MISSOURI STATE DEPT/ HEALTH & SENIOR SRV in support of the above referenced project. This award is pursuant to the authority of Section 546 of the Public Health and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

This award addresses the following Amendment action: Change in Terms and Conditions

Award recipients may access the SAMHSA website at www.samhsa.gov (click on “Grants” then SAMHSA Grants Management), which provides information relating to the Division of Payment Management System, HHS Division of Cost Allocation and Postaward Administration Requirements. Please use your grant number for reference.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

If you have any questions about this award, please contact your Grants Management Specialist and your Government Project Officer listed in your terms and conditions.

Sincerely yours,
Mercedes Martinez  
Grants Management Officer  
Division of Grants Management

See additional information below
SECTION I – AWARD DATA – 6H79SP080319-03M001

Award Calculation (U.S. Dollars)

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personnel(non-research)</td>
<td>$37,282</td>
</tr>
<tr>
<td>Fringe Benefits</td>
<td>$21,623</td>
</tr>
<tr>
<td>Travel</td>
<td>$2,335</td>
</tr>
<tr>
<td>Supplies</td>
<td>$564,407</td>
</tr>
<tr>
<td>Contractual</td>
<td>$160,000</td>
</tr>
<tr>
<td>Other</td>
<td>$1,806</td>
</tr>
<tr>
<td>Direct Cost</td>
<td>$787,453</td>
</tr>
<tr>
<td>Indirect Cost</td>
<td>$12,547</td>
</tr>
<tr>
<td>Approved Budget</td>
<td>$800,000</td>
</tr>
<tr>
<td>Federal Share</td>
<td>$800,000</td>
</tr>
<tr>
<td>Cumulative Prior Awards for this Budget Period</td>
<td>$800,000</td>
</tr>
</tbody>
</table>

AMOUNT OF THIS ACTION (FEDERAL SHARE) $0

<table>
<thead>
<tr>
<th>YR</th>
<th>AMOUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>$800,000</td>
</tr>
</tbody>
</table>

*Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

Fiscal Information:

<table>
<thead>
<tr>
<th>CFDA Number</th>
<th>93.243</th>
</tr>
</thead>
<tbody>
<tr>
<td>EIN</td>
<td>[blank]</td>
</tr>
<tr>
<td>Document Number</td>
<td>17SP80319A</td>
</tr>
<tr>
<td>Fiscal Year</td>
<td>2019</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IC</th>
<th>CAN</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>TI</td>
<td>C96N705</td>
<td>$0</td>
</tr>
<tr>
<td>IC</td>
<td>C96N705</td>
<td>2019</td>
</tr>
<tr>
<td>TI</td>
<td>C96N705</td>
<td>$0</td>
</tr>
</tbody>
</table>

SP Administrative Data:

PCC: FR-CARA / OC: 4145

SECTION II – PAYMENT/HOTLINE INFORMATION – 6H79SP080319-03M001

Payments under this award will be made available through the HHS Payment Management System (PMS). PMS is a centralized grants payment and cash management system, operated by the HHS Program Support Center (PSC), Division of Payment Management (DPM). Inquiries regarding payment should be directed to: The Division of Payment Management System, PO Box 6021, Rockville, MD 20852, Help Desk Support – Telephone Number: 1-877-614-5533.

SECTION III – TERMS AND CONDITIONS – 6H79SP080319-03M001

This award is based on the application submitted to, and as approved by, SAMHSA on the above-title project and is subject to the terms and conditions incorporated either directly or by reference in the following:

a. The grant program legislation and program regulation cited in this Notice of Award.
b. The restrictions on the expenditure of federal funds in appropriations acts to the extent those restrictions are pertinent to the award.
c. 45 CFR Part 75 as applicable.
d. The HHS Grants Policy Statement.
e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

Treatment of Program Income:
Additional Costs

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than $10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75.

SECTION IV – SP Special Terms and Conditions – 6H79SP080319-03M001

SPECIAL TERMS

MJ Grant Language

Grant funds may not be used, directly or indirectly, to purchase, prescribe, or provide marijuana or treatment using marijuana. Treatment in this context includes the treatment of opioid use disorder. Grant funds also cannot be provided to any individual who or organization that provides or permits marijuana use for the purposes of treating substance use or mental disorders. See, e.g., 45 C.F.R. § 75.300(a) (requiring HHS to “ensure that Federal funding is expended . . . in full accordance with U.S. statutory . . . requirements.”); 21 U.S.C. §§ 812(c)(10) and 841 (prohibiting the possession, manufacture, sale, purchase or distribution of marijuana). This prohibition does not apply to those providing such treatment in the context of clinical research permitted by the DEA and under an FDA-approved investigational new drug application where the article being evaluated is marijuana or a constituent thereof that is otherwise a banned controlled substance under federal law.

Please email any related questions to MJQuestions@SAMHSA.HHS.GOV

SPECIAL CONDITIONS

MJ Attestation Letter

No later than November 18, 2019, please submit a response through eRA Commons.

Please submit an attestation statement certifying that the grantee organization/recipient, State and all sub-recipients (contractor & sub-awardee) will comply with the following Special Term of
Award.

The attestation statement should read: I certify that the grantee organization/recipient, State and all sub-recipients will comply with the following NoA language:

Grant funds may not be used, directly or indirectly, to purchase, prescribe, or provide marijuana or treatment using marijuana. Treatment in this context includes the treatment of opioid use disorder. Grant funds also cannot be provided to any individual who or organization that provides or permits marijuana use for the purposes of treating substance use or mental disorders. See, e.g., 45 C.F.R. § 75.300(a) (requiring HHS to "ensure that Federal funding is expended . . . in full accordance with U.S. statutory . . . requirements."); 21 U.S.C. §§ 812(c)(10) and 841 (prohibiting the possession, manufacture, sale, purchase or distribution of marijuana). This prohibition does not apply to those providing such treatment in the context of clinical research permitted by the DEA and under an FDA-approved investigational new drug application where the article being evaluated is marijuana or a constituent thereof that is otherwise a banned controlled substance under federal law.

The attestation statement must be on letterhead and signed by the Authorized Representative or Business Official.

Please email any related questions to MJQuestions@SAMHSA.HHS.GOV

All responses to award terms and conditions must be submitted as .pdf documents in the “View Terms Tracking Details” page in eRA Commons.

For more information on how to upload a document in response to a tracked term, please reference the SAMHSA training materials on the website, which include a video to provide SAMHSA grantees a brief overview of Terms and Conditions in eRA Commons, and how to respond to tracked terms and conditions listed in your Notice of Award located at https://youtu.be/GJT74T-r_b; and a terms and conditions reference sheet located at https://www.samhsa.gov/sites/default/files/grants/grantee_terms_reference_sheet.pdf.

All previous terms and conditions remain in effect until specifically approved and removed by the Grants Management Officer.

Staff Contacts:

MORRIS FLOOD, Program Official
Phone: 240-276-2479  Email: Morris.Flood@samhsa.hhs.gov

Mercedes Martinez, Grants Specialist
Phone: (240) 276-1417  Email: Mercedes.Martinez@samhsa.hhs.gov  Fax: (240) 276-1420